A Phase Ib/IIa Study Evaluating the Safety and Tolerability of Vitamin C in Patients with Intermediate or high Risk Myelodysplastic Syndrome with TET2 Mutations
Brief description of study
If you have been diagnosed with intermediate or high risk Myelodysplastic Syndrome with a mutation in the Tet methylcytosine dioxygenase (abbreviated as TET) gene, you may be qualified for this Phase Ib/IIa study. The main goal of this study is to test the safety and to see how well a high dose of vitamin C works in subjects with high risk Myelodysplastic Syndrome.
Clinical Study Identifier: s17-00978
ClinicalTrials.gov Identifier: NCT03433781
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
